ACAD
Acadia Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
EPS Beats Expectation
RSI Overbought
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ACAD
Acadia Pharmaceuticals Inc.
A biopharmaceutical company that developing medicines for central nervous system disorders
12830 El Camino Real, Suite 400, San Diego, California 92130
--
Founded in Vermont in 1993, Acadia Pharmaceuticals Inc., is a biopharmaceutical company focused on the development and commercialization of innovative micromolecular drugs to address unmet medical needs in neurological and central nervous system diseases. The company has a series of product candidates, led by pimavanserin, which is in the third stage of development for the treatment of Parkinson's disease. The company has successfully completed the pivotal Phase 3 trial and the company plans to submit a new drug application to the US Food and Drug Administration by the end of 2014. Pimavanserin is in the second phase of Alzheimer's treatment development and has successfully completed the second phase of trials as a synergistic treatment for Alzheimer's disease. The company's products also include a chronic pain and glaucoma clinical-stage program with Allergan, as well as two advanced clinical programs for the treatment of Parkinson's disease and other neurological diseases. All of the company's candidate products and projects come from internal research and development.
Earnings Call
Q2/2025
Estimate EPS0.14
Actual EPS0.16
Estimate Revenue262.07M
Actual Revenue264.60M
Contradictions in DAYBUE and NUPLAZID Growth: Insights from the Latest Earnings Call
Aug 11,2025 06:39
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ACAD has released its 2025 Q3 earnings. EPS was reported at 0.26, versus the expected 0.15, beating expectations. The chart below visualizes how ACAD has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ACAD has released its 2025 Q3 earnings report, with revenue of 278.63M, reflecting a YoY change of 11.27%, and net profit of 71.78M, showing a YoY change of 119.07%. The Sankey diagram below clearly presents ACAD's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
